Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyowa Adjusting Cymbalta Generic Supply before Launch as Rivals Delay Release
June 18, 2021
- Nichi-Iko Licenses Its Remicade Biosimilar to Argentine Drug Maker
June 18, 2021
- Delays in Cymbalta Generic Launch Stir Worries on Demand Spike for 2 Makers
June 17, 2021
- Astellas Offloads 5 Legacy Products to Germany’s Cheplapharm
June 17, 2021
- Daiichi Sankyo Ships AstraZeneca COVID-19 Vaccine to Taiwan, Vietnam
June 17, 2021
- Kitasato Institute, Meiji Eye Ivermectin Derivative Use for Post-COVID-19 Symptoms Too
June 16, 2021
- Enhertu Enters PIII for 1st Line HER2-Positive Breast Cancer
June 16, 2021
- Daiichi Sankyo Drops Nafamostat Development for COVID-19
June 16, 2021
- Rohto Initiates Japan PII of Stem Cell Therapy for Severe COVID-19 Pneumonia
June 16, 2021
- Eisai to Transfer Zonegran’s European Rights to UK Firm
June 16, 2021
- Shipment Curbs of 3,000-Plus Products Taking a Toll on Wholesalers as Generic Woes Continue
June 15, 2021
- Opdivo Gets 2 New Indications in South Korea: Ono
June 15, 2021
- Honjo Ups Royalty Claim after Tecentriq Settlement: Opdivo Row
June 14, 2021
- Japan Approves J-TEC’s Mucosal Cell Sheet for Corneal Stem Cell Deficiency
June 14, 2021
- Chugai Files Bispecific Antibody Faricimab for DME, nAMD in Japan
June 14, 2021
- Japan Approves 1st Oncolytic Virus, Delytact, for Malignant Glioma
June 14, 2021
- Ono to Ditch Foipan Development for COVID-19 as it Misses Goal in Japan PIII
June 14, 2021
- Astellas, Otsuka, Meiji Joining Workplace Vaccination Campaign
June 11, 2021
- NanoCarrier Gene Therapy VB-111 Enters PIII in Japan
June 11, 2021
- Global Pharma Market Grows to US$1.18 Trillion in 2020, with Humira Maintaining No. 1 Title: IQVIA
June 11, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…